Novartis (NVS.US) "twice yearly" long-acting cholesterol-lowering drug initiates new Phase III clinical trial.

According to the Zhtng Cijng APP, on August 4th, ClinicalTrials.gov website showed that Novartis (NVS.US) registered a Phase III clinical trial of Enoxaparin sodium, aimed at evaluating the efficacy and safety of early initiation of Enoxaparin sodium treatment in patients hospitalized with acute coronary syndrome (ACS). This is a multicenter, randomized, double-blind, placebo-controlled study, with subjects being patients who have recently experienced ACS, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients.